

EMISPHERE TECHNOLOGIES INC

Form 424B3

November 08, 2011

Table of Contents

**Filed Pursuant to Rule 424(b)(3) and Rule 424(c)
Registration No. 333-175794**

**PROSPECTUS SUPPLEMENT NO. 1
7,310,744 Shares of Common Stock**

This Prospectus Supplement No. 1 (the "Prospectus Supplement") amends our Prospectus dated October 12, 2011 (the "Prospectus"). The Prospectus relates to the offer for sale by the existing holders of our common stock, par value \$0.01 per share, named in the Prospectus of 7,310,744 shares of our common stock, including 3,010,306 shares of our common stock issuable upon exercise of the warrants held by the selling security holders. These existing holders of our common stock are referred to as selling security holders throughout this Prospectus Supplement.

All of the shares of common stock offered by this Prospectus Supplement are being sold by the selling security holders. It is anticipated that the selling security holders will sell these shares of common stock from time to time in one or more transactions, in negotiated transactions or otherwise, at prevailing market prices or at prices otherwise negotiated. We will not receive any proceeds from the sales of shares of common stock by the selling security holders. This Prospectus Supplement is being filed to include the information set forth in our Quarterly Report on Form 10-Q for our fiscal quarter ended September 30, 2011, filed with the Securities and Exchange Commission ("SEC") on November 8, 2011, which is attached hereto.

This Prospectus Supplement should be read in conjunction with the Prospectus, and is qualified by reference to the Prospectus except to the extent that the information in this Prospectus Supplement supersedes the information contained therein.

Our common stock is currently traded on the Over-The-Counter Bulletin Board, commonly known as the OTC Bulletin Board ("OTCBB"), under the symbol "EMIS.OB". As of November 7, 2011, the closing sale price of our common stock was \$1.69 per share.

Investing in our securities involves substantial risks. You should carefully consider the matters discussed under the section entitled "Risk Factors" beginning on page 6 of the Prospectus.

Neither the SEC nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. The date of this prospectus supplement is November 8, 2011.

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q**

(Mark One)

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**

For the quarterly period ended September 30, 2011

OR

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**

For the transition period from _____ to _____

**Commission File Number 000-17758
EMISPHERE TECHNOLOGIES, INC.**

(Exact name of registrant as specified in its charter)

DELAWARE

13-3306985

(State or jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification Number)

**240 Cedar Knolls Rd, Suite 200
Cedar Knolls, NJ**

07927

(Address of principal executive offices)

(Zip Code)

(973) 532-8000

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐

Accelerated filer ☒

Non-accelerated filer ☐
(Do not check if a smaller
reporting company)

Smaller reporting
company ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes ☐ No ☒

The number of shares of the Registrant's common stock, \$.01 par value, outstanding as of November 1, 2011 was 60,687,478.

EMISPHERE TECHNOLOGIES, INC.
Index

<u>PART I. FINANCIAL INFORMATION</u>	3
<u>Item 1. Financial Statements:</u>	3
<u>Condensed Balance Sheets as of September 30, 2011 (unaudited) and December 31, 2010</u>	3
<u>Condensed Statements of Operations for the three and nine months ended September 30, 2011 and 2010 (unaudited)</u>	4
<u>Condensed Statements of Cash Flows for the nine months ended September 30, 2011 and 2010 (unaudited)</u>	5
<u>Notes to Condensed Financial Statements (unaudited)</u>	6
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	18
<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>	23
<u>Item 4T. Controls and Procedures</u>	23
<u>PART II. OTHER INFORMATION</u>	24
<u>Item 1A. Risk Factors</u>	24
<u>Item 6. Exhibits</u>	25
<u>SIGNATURES</u>	27
<u>EXHIBIT INDEX</u>	28

All other items called for by the instructions to Form 10-Q have been omitted because the items are not applicable or the relevant information is not material.

Table of Contents**PART I****ITEM 1. FINANCIAL STATEMENTS**

EMISPHERE TECHNOLOGIES, INC.
CONDENSED BALANCE SHEETS
September 30, 2011 and December 31, 2010
(in thousands, except share and per share data)

	September 30, 2011 (unaudited)	December 31, 2010
Assets:		
Current assets:		
Cash and cash equivalents	\$ 4,729	\$ 5,326
Accounts receivable, net	35	14
Inventories	258	260
Prepaid expenses and other current assets	483	496
Total current assets	5,505	6,096
Equipment and leasehold improvements, net	51	82
Purchased technology, net	658	838
Restricted cash	260	260
Total assets	\$ 6,474	\$ 7,276
Liabilities and Stockholders Deficit:		
Current liabilities		
Accounts payable and accrued expenses	\$ 981	\$ 2,954
Notes payable related party, including accrued interest and net of related discount	24,475	
Derivative instruments:		
Related party	24,981	17,293
Others	8,839	5,647
Contract termination liability, current		435
Restructuring accrual, current		300
Other current liabilities	41	35
Total current liabilities	59,317	26,664
Notes payable related party, including accrued interest and net of related discount		20,385
Deferred revenue	31,578	31,535
Derivative instrument related party		11,166
Deferred lease liability and other liabilities	16	46
Total liabilities	90,911	89,796
Stockholders deficit:		
Preferred stock, \$.01 par value; authorized 1,000,000 shares; none issued and outstanding		

Edgar Filing: EMISPHERE TECHNOLOGIES INC - Form 424B3

Common stock, \$.01 par value; authorized 100,000,000 shares; issued 60,977,210 shares (60,687,478 outstanding) as of September 30, 2011 and issued 52,178,834 shares (51,889,102 outstanding) as December 31, 2010	610	522
Additional paid-in-capital	404,613	401,853
Accumulated deficit	(485,708)	(480,943)
Common stock held in treasury, at cost; 289,732 shares	(3,952)	(3,952)
Total stockholders' deficit	(84,437)	(82,520)
Total liabilities and stockholders' deficit	\$ 6,474	\$ 7,276

The accompanying notes are an integral part of the financial statements.

Table of Contents

EMISPHERE TECHNOLOGIES, INC.
CONDENSED STATEMENT OF OPERATIONS
For the three and nine months ended September 30, 2011 and 2010
(in thousands, except share and per share data)
(unaudited)

	For the three months ended September 30,		For the nine months ended September 30,	
	2011	2010 Restated	2011	2010 Restated
Net Sales	\$	\$ 4	\$	\$ 55
Costs and expenses:				
Research and development	424	690	1,516	1,984
General and administrative	1,037	2,516	4,080	6,979
Restructuring costs				50
Gain on disposal of fixed assets				(1)
Expense from settlement of lawsuit		58		278
Contract termination expense		542		542
Depreciation and amortization	70	73	210	223
Total costs and expenses	1,531	3,879	5,806	10,055
Operating loss	(1,531)	(3,875)	(5,806)	(10,000)
Other non-operating income (expense):				
Other income	4	2	73	7
Sale of patent		500		500
Change in fair value of derivative instruments				
Related party	(9,700)	11,766	6,345	(3,562)
Other	(4,931)	2,831	(1,270)	(4,440)
Interest expense				
Related party	(1,448)	(1,138)	(4,090)	(1,997)
Other		(4)	(16)	(386)
Loss on extinguishment of debt				(17,014)
Financing fees				(1,858)
Total other non-operating income (expense)	(16,075)	13,957	1,042	(28,750)
Net income (loss)	\$ (17,606)	\$ 10,082	\$ (4,764)	\$ (38,750)
Net income (loss) per share, basic	\$ (0.29)	\$ 0.21	\$ (0.09)	\$ (0.87)
Net income (loss) per share, diluted	\$ (0.29)	\$ 0.20	\$ (0.09)	\$ (0.87)
Weighted average shares outstanding, basic	60,122,747	47,401,395	54,811,423	44,291,889
Weighted average shares outstanding, diluted	60,122,747	50,922,881	54,811,423	44,291,889

The accompanying notes are an integral part of the financial statements.

Table of Contents

EMISPHERE TECHNOLOGIES, INC.
CONDENSED STATEMENTS OF CASH FLOWS
For the nine months ended September 30, 2011 and 2010
(in thousands)
(unaudited)

	For the nine months ended September 30,	
	2011	2010
Cash flows from operating activities:		
Net loss	\$ (4,764)	\$ (38,750)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation	31	44
Amortization	179	179
Change in fair value of derivative instruments	(5,075)	8,003
Non-cash interest expense	4,091	21,254
Non-cash compensation expense	220	685
Gain on disposal of fixed assets		(1)
Changes in assets and liabilities excluding non-cash transactions:		
(Increase) decrease in accounts receivable	(21)	99
Decrease (increase) in inventory	2	(24)
Decrease (increase) in prepaid expenses and other current assets	13	(387)
Increase in deferred revenue	43	2,069
Decrease in accounts payable and accrued expenses	(2,408)	(516)
Increase in other current liabilities	6	415
Decrease in deferred lease liability	(30)	(25)
Decrease in restructuring accrual	(300)	(300)
Total adjustments	(3,249)	31,495
Net cash used in operating activities	(8,013)	(7,255)
Net cash provided by investing activities proceeds from sale of fixed assets		1
Cash flows provided by financing activities		
Exercise of warrants	236	
Proceeds from the issuance of common stock	7,174	6,674
Exercise of options	6	
Proceeds from notes payable		500
Payment on notes payable		(525)
Net cash provided by financing activities	7,416	6,649
Net decrease in cash and cash equivalents	(597)	(605)
Cash and cash equivalents, beginning of period	5,326	3,566
Cash and cash equivalents, end of period	4,729	\$ 2,961
Schedule of non-cash financing activities		

Edgar Filing: EMISPHERE TECHNOLOGIES INC - Form 424B3

Common stock issued to settle accrued Directors compensation	\$	\$	11
Exchange of debt as deferred revenue	\$	\$	13,000
Reclassification of derivative liability to equity upon exercise of warrants	\$	349	\$

The accompanying notes are an integral part of the financial statements.

Table of Contents

**EMISPHERE TECHNOLOGIES, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS**

1. Nature of Operations and Liquidity

Nature of Operations. Emisphere Technologies, Inc. (Emisphere, the Company, our, us, or we) is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules or nutritional supplements using its Eligen® Technology. These molecules are currently available or are under development. Our core business strategy is to develop oral forms of drugs or nutrients that are not currently available or have poor bioavailability in oral form, by applying the Eligen® Technology to those drugs or nutrients. Our development efforts are conducted internally or in collaboration with corporate development partners. Typically, the drugs that we target are at an advanced stage of development, or have already received regulatory approval, and are currently available on the market.

Liquidity. As of September 30, 2011, we had approximately \$4.7 million in cash and cash equivalents, approximately \$53.8 million in working capital deficiency, a stockholders' deficit of approximately \$84.4 million and an accumulated deficit of approximately \$485.7 million. Our operating loss for the three months ended September 30, 2011 was approximately \$1.5 million and \$5.8 million for the nine months ended September 30, 2011.

On June 30, 2011, we entered into a securities purchase agreement with various institutional investors to sell an aggregate of 4,300,438 shares of our common stock and warrants to purchase a total of 3,010,306 shares of our common stock for gross proceeds, before deducting fees and expenses and excluding the proceeds, if any, from the exercise of the warrants, of \$3,749,982 (the 2011 Private Placement). The 2011 Private Placement closed on July 6, 2011. In connection with the 2011 Private Placement, we entered into a securities purchase agreement on the same date with MHR Fund Management LLC to sell an aggregate of 4,300,438 shares of our common stock and warrants to purchase a total of 3,010,306 shares of our common stock for gross proceeds, before deducting fees and expenses and excluding the proceeds, if any, from the exercise of the warrants, of \$3,749,982 (the 2011 MHR Private Placement). Simultaneous with closing the 2011 Private Placement, we closed the 2011 MHR Private Placement with MHR Fund Management LLC and certain of its affiliated investment funds (collectively, MHR). In connection with the 2011 Private Placement and the 2011 MHR Private Placement, we entered into a waiver agreement with MHR, pursuant to which MHR waived certain anti-dilution adjustment rights under its senior secured notes and certain warrants that would otherwise have been triggered by the 2011 Private Placement. As consideration for such waiver, we issued to MHR warrants to purchase 795,000 shares of our common stock and agreed to reimburse MHR for up to \$25,000 of its legal fees. In both the 2011 Private Placement and the 2011 MHR Private Placement (together, the July 2011 Financing), each unit, consisting of one share of common stock and a warrant to purchase 0.7 shares of common stock, was sold at a purchase price of \$0.872. All of the warrants issued in the July 2011 Financing are exercisable at an exercise price of \$1.09 per share and will expire on July 6, 2016.

We anticipate that we will continue to generate significant losses from operations for the foreseeable future, and that our business will require substantial additional investment that we have not yet secured. As such, we anticipate that our existing cash resources will enable us to continue operations through approximately May 2012, or earlier if unforeseen events arise that negatively affect our liquidity. Further, we have significant future commitments and obligations. These conditions raise substantial doubt about our ability to continue as a going concern. Consequently, the audit opinion issued by our independent registered public accounting firm relating to our financial statements for the year ended December 31, 2010 contained a going concern explanatory paragraph. We are pursuing new and enhanced collaborations and exploring other funding options, with the objective of minimizing dilution and disruption.

Our plan is to raise capital when needed and/or to pursue product partnering opportunities. We expect to continue to spend substantial amounts on research and development, including amounts spent on conducting clinical trials for our product candidates. Expenses will be partially offset with income-generating license agreements, if possible. Further, we will not have sufficient resources to develop fully any new products or technologies unless we are able to raise substantial additional financing on acceptable terms or secure funds from new or existing partners. We cannot assure that financing will be available when needed, or on favorable terms or at all. If additional capital is raised through the sale of equity or convertible debt securities, the issuance of such securities would result in dilution to our existing

stockholders. Our failure to raise capital before May 2012 will adversely affect our business, financial condition and results of operations, and could force us to reduce or cease our operations. No adjustment has been made in the accompanying financial statements to the carrying amount and classification of recorded assets and liabilities should we be unable to continue operations.

Table of Contents

2. Basis of Presentation

The condensed balance sheet at December 31, 2010 was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. The other information in these condensed financial statements is unaudited but, in the opinion of management, reflects all adjustments necessary for a fair presentation of the results for the periods covered. All such adjustments are of a normal recurring nature unless disclosed otherwise. These condensed financial statements, including notes, have been prepared in accordance with the applicable rules of the Securities and Exchange Commission and do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. These condensed financial statements should be read in conjunction with the financial statements and additional information as contained in our Annual Report on Form 10-K for the year ended December 31, 2010.

3. Stock-Based Compensation Plans

On April 20, 2007, the stockholders of the Company approved the 2007 Stock Award and Incentive Plan (the "2007 Plan"). The 2007 Plan provides for grants of options, stock appreciation rights, restricted stock, deferred stock, bonus stock and awards in lieu of obligations, dividend equivalents, other stock-based awards and performance awards to executive officers and other employees of the Company, and non-employee directors, consultants and others who provide substantial service to us. The 2007 Plan provides for the issuance of an aggregate 3,275,334 shares as follows: 2,500,000 new shares, 374,264 shares remaining and transferred from the Company's 2000 Stock Option Plan (the "2000 Plan") (which was then replaced by the 2007 Plan) and 401,070 shares remaining and transferred from the Company's Stock Option Plan for Outside Directors (the "Directors Stock Plan"). In addition, shares canceled, expired, forfeited, settled in cash, settled by delivery of fewer shares than the number underlying the award, or otherwise terminated under the 2000 Plan will become available for issuance under the 2007 Plan.

As of September 30, 2011, shares available for future grants under the Plans amounted to 1,367,598.

Total compensation expense recorded during the three months ended September 30, 2011 for share-based payment awards was \$0.08 million, of which \$0.01 million is included in research and development and \$0.07 million is included in general and administrative expenses in the condensed statement of operations for the three months ended September 30, 2011. Total compensation expense recorded during the nine months ended September 30, 2011 for share-based payment awards was \$0.22 million, of which \$0.04 million is included in research and development and \$0.18 million is included in general and administrative expenses in the condensed statement of operations for the nine months ended September 30, 2011. At September 30, 2011, total unrecognized estimated compensation expense related to non-vested stock options granted prior to that date was \$0.5 million, which is expected to be recognized over a weighted-average period of approximately two years. Ten thousand options were exercised in the nine months ended September 30, 2011 and no options were exercised in the nine months ended September 30, 2010. No tax benefit was realized due to a continued pattern of operating losses.

During the nine months ended September 30, 2011, the Company granted 309,000 options which included 20,000 options to Gary Riley, 30,000 options to Michael Garone and 40,000 each to Mark Rachesky, Michael Weiser, John Harkey and Timothy Rothwell.

4. Inventories

Inventories are stated at the lower of cost or market determined by the first in, first out method. Inventories consist principally of finished goods at September 30, 2011 and December 31, 2010.

Table of Contents**5. Prepaid Expenses and Other Current Assets**

Prepaid expenses and other current assets consist of the following:

	September 30, 2011	December 31, 2010
	(in thousands)	
Prepaid corporate insurance	\$ 29	\$ 41
Deposit on inventory	420	420
Prepaid expenses and other current assets	34	35
	\$ 483	\$ 496

6. Fixed Assets

Equipment and leasehold improvements, net, consists of the following:

	Useful Lives in Years	September 30, 2011	December 31, 2010
		(in thousands)	
Equipment	3-7	\$ 1,370	\$ 1,370
Leasehold improvements	Term of lease	61	61
		1,431	1,431
Less, accumulated depreciation and amortization		1,380	1,349
Equipment and leasehold improvements, net		\$ 51	\$ 82

7. Purchased Technology

Purchased technology represents the value assigned to patents and the rights to utilize, sell or license certain technology in conjunction with our proprietary carrier technology. These assets are utilized in various research and development projects. Purchased technology is amortized over a period of 15 years, which represents the average life of the patents.

	September 30, 2011	December 31, 2010
	(in thousands)	
Gross carrying amount	\$ 4,533	\$ 4,533
Less, accumulated amortization	3,875	3,695
Net book value	\$ 658	\$ 838

Amortization expense for the purchased technology is approximately \$60 thousand per quarter in 2011 and in the remaining years through 2014.

8. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following:

	September 30, 2011	December 31, 2010
	(In thousands)	
Accounts payable and other accrued expenses	\$ 383	\$ 2,201
Accrued bonus		300
Accrued legal, professional fees and other	512	375
Accrued vacation	47	69
Clinical trial expenses and contract research	39	9
	\$ 981	\$ 2,954

9. Notes Payable

Notes payable consist of the following:

8

Table of Contents

	September 30, 2011	December 31, 2010
	(in thousands)	
MHR Convertible Notes	\$ 23,914	\$ 19,864
MHR Promissory Notes	561	521
	\$ 24,475	\$ 20,385

MHR Convertible Notes. On September 26, 2005, we received net proceeds of approximately \$12.9 million under a \$15 million secured loan agreement (the **Loan Agreement**) executed with MHR Fund Management LLC (together with its affiliates, **MHR**). Under the Loan Agreement, MHR requested, and on May 16, 2006, we effected, the exchange of the loan from MHR for senior secured convertible notes (the **MHR Convertible Notes**) with substantially the same terms as the Loan Agreement, except that the MHR Convertible Notes are convertible, at the sole discretion of MHR, into shares of our common stock at a price per share of \$3.78. As of September 30, 2011, the MHR Convertible Notes were convertible into 7,246,873 shares of our common stock. The MHR Convertible Notes are due on September 26, 2012, bear interest at 11% and are collateralized by a first priority lien in favor of MHR on substantially all of our assets. Interest is payable in the form of additional MHR Convertible Notes rather than in cash. Effective September 27, 2011, the MHR Convertible Notes were reclassified as a short term liability in accordance with their September 26, 2012 maturity date.

In connection with the Loan Agreement, we amended MHR's previously existing warrants to purchase 387,374 shares of common stock (**MHR 2005 Warrants**) to provide additional anti-dilution protection. We also granted MHR the option (**MHR Option**) to purchase warrants for up to 617,211 shares of our common stock. The MHR Option was exercised during April 2006 whereby MHR acquired 617,211 warrants (**MHR 2006 Warrants**) to acquire an equal number of shares of common stock. The exercise price for the MHR Option was \$0.01 per warrant for the first 67,084 warrants and \$1.00 per warrant for each additional warrant. See Note 10 for a further discussion of the liability related to these warrants.

Total issuance costs associated with the Loan Agreement were \$2.1 million, of which \$1.9 million were allocated to the MHR Convertible Notes, and \$0.2 million were allocated to the related derivative instruments. Of the \$1.9 million allocated to the MHR Convertible Notes, \$1.4 million represents reimbursement of MHR's legal fees and \$0.5 million represents our legal and other transaction costs. The \$1.4 million paid on behalf of the lender has been recorded as a reduction of the face value of the note, while the \$0.5 million of our costs has been recorded as deferred financing costs.

The MHR Convertible Notes provide MHR with the right to require us to redeem the notes in the event of a change in control. The change in control redemption feature has been determined to be an embedded derivative instrument which must be separated from the host contract. For the year ended December 31, 2006, the fair value of the change in control redemption feature was estimated using a combination of a put option model for the penalties and the Black-Scholes model for the conversion option that would exist under the MHR Convertible Notes. The estimate resulted in a value that was de minimis and, therefore, no separate liability was recorded. Changes in the assumptions used to estimate the fair value of this derivative instrument, in particular the probability that a change in control will occur, could result in a material change to the fair value of the instrument. For the nine months ended September 30, 2011 and for the years ended December 31, 2010, 2009 and 2008, management determined the probability of exercise of the right due to change in control to be remote. The fair value of the change in control redemption feature is de minimis.

In connection with the MHR Convertible Notes financing, the Company agreed to appoint a representative of MHR (**MHR Nominee**) and another person (the **Mutual Director**) to its Board of Directors. Further, the Company agreed to amend, and in January 2006 did amend, its certificate of incorporation to provide for continuity of the MHR Nominee and the Mutual Nominee on the Board, as described therein, so long as MHR holds at least 2% of the outstanding

common stock of the Company.

The MHR Convertible Notes provide for various events of default including the failure to perfect any of the liens in favor of MHR, failure to observe any covenant or agreement, failure to maintain the listing and trading of our common stock, sale of a substantial portion of our assets, merger with another entity without the prior consent of MHR, or any governmental action that renders us unable to honor or perform our obligations under the Loan Agreement or results in a material adverse effect on our operations. If an event of default occurs, the MHR Convertible Notes provide for the immediate repayment and certain additional amounts as set forth in the MHR Convertible Notes. We currently have a waiver from MHR for failure to perfect liens on certain intellectual property rights through September 26, 2012.

Effective January 1, 2009, the Company adopted the provisions of the Financial Accounting Standards Board (FASB) Accounting Codification Topic 815-40-15-5, *Evaluating Whether an Instrument Involving a Contingency is Considered Indexed to an Entity's Own Stock* (FASB ASC 815-40-15-5). Under FASB ASC 815-40-15-5, the conversion feature embedded in the MHR Convertible

Table of Contents

Notes have been bifurcated from the host contract and accounted for separately as a derivative. The bifurcation of the embedded derivative increased the amount of debt discount thereby reducing the book value of the MHR Convertible Notes and increasing prospectively the amount of interest expense to be recognized over the life of the MHR Convertible Notes using the effective yield method.

As consideration for its consent and limitation of rights in connection with the Master Agreement and Amendment by and between the Company and Novartis dated as of June 4, 2010 (the *Novartis Agreement*), the Company granted MHR warrants to purchase 865,000 shares of its common stock (the *June 2010 MHR Warrants*) under the MHR Letter Agreement (as defined below). The Company estimated the fair value of the June 2010 MHR Warrants on the date of grant using Black-Scholes models to be \$1.9 million. The Company determined that the resulting modification of the MHR Convertible Notes was substantial in accordance with FASB ASC 470-50, *Modifications and Extinguishments*. As such, the modification of the MHR Convertible Notes was accounted for as an extinguishment and restructuring of the debt, and the warrants issued to MHR were expensed as a financing fee. The fair value of the MHR Convertible Notes as of June 4, 2010 was estimated by calculating the present value of future cash flows discounted at a market rate of return for comparable debt instruments to be \$17.2 million. The Company recognized a loss on extinguishment of debt in the amount of \$17.0 million which represented the difference between the net carrying amount of the MHR Convertible Notes and their fair value as of the date of the Novartis Agreement and the MHR Letter Agreement.

The book value of the MHR Convertible Notes is comprised of the following:

	September 30, 2011	December 31, 2010
	(in thousands)	
Face Value of the notes (including accrued interest)	\$ 27,393	\$ 25,233
Discount (related to the warrant purchase option and embedded conversion feature)	(3,479)	(5,369)
	\$ 23,914	\$ 19,864

2010 MHR Promissory Notes. In connection with the Novartis Agreement, the Company and MHR entered into a letter agreement (the *MHR Letter Agreement*), and MHR, the Company and Novartis entered into a non-disturbance agreement (the *Non-Disturbance Agreement*), which was a condition to Novartis' execution of the Novartis Agreement. Pursuant to the MHR Letter Agreement, MHR agreed to limit certain rights and courses of action that it would have available to it as a secured party under the Senior Secured Term Loan Agreement and Pledge and Security Agreement (*Loan and Security Agreement*) between MHR and the Company. MHR also consented to the Novartis Agreement, which consent was required under the Loan and Security Agreement, and MHR also agreed to enter into a comparable agreement at some point in the future in connection with another potential Company transaction (the *Future Transaction Agreement*). The MHR Letter Agreement also provided for the Company to reimburse MHR for its legal fees incurred in connection with the Non-Disturbance Agreement for up to \$500,000 and up to \$100,000 in legal expenses incurred by MHR in connection with the Future Transaction Agreement. The reimbursements were to be paid in the form of non-interest bearing promissory notes issued on the effective date of the MHR Letter Agreement. As such, the Company issued to MHR non-interest promissory notes for \$500,000 and \$100,000 on June 8, 2010 (collectively, the *2010 MHR Promissory Notes*). The Company received documentation that MHR expended more than the \$500,000 of legal fees in connection with the Non-Disturbance Agreement and \$100,000 of legal fees in connection with the Future Transaction Agreement, and, consequently, recorded the issuance of the 2010 MHR Promissory Notes and a corresponding charge to financing expenses. The 2010 MHR Promissory Notes are due June 4, 2012. The Company imputed interest at its incremental borrowing rate of 10%, and discounted the face amounts of the 2010 MHR Promissory Notes. As of September 30, 2011, the unamortized discount of the \$500,000 and \$100,000 promissory notes are \$33,000 and \$7,000, respectively.

Table of Contents**10. Derivative Instruments**

Derivative instruments consist of the following:

	September 30, 2011	December 31, 2010
	(in thousands)	
MHR Convertible Note	\$ 5,905	11,166
MHR 2006 Warrants		646
August 2007 Warrants	132	481
August 2009 Warrants	6,094	7,807
June 2010 MHR Warrants	1,092	1,495
August 2010 Warrants	7,952	10,550
August 2010 MHR Waiver Warrants	1,533	1,961
July 2011 Warrants	9,816	
July 2011 MHR Waiver Warrants	1,296	
	\$ 33,820	\$ 34,106

The fair value of the warrants that have exercise price reset features is estimated using an adjusted Black-Scholes model. The Company computes valuations each quarter, using Black-Scholes model calculations for such warrants to account for the various possibilities that could occur due to various circumstances that could arise in connection with the contractual terms of said instruments. The Company weights each Black-Scholes model calculation based on its estimation of the likelihood of the occurrence of each circumstance and adjusts relevant Black-Scholes model input to calculate the value of the derivative at the reporting date.

Embedded Conversion Feature of MHR Convertible Notes. The MHR Convertible Notes contain a provision whereby the conversion price is adjustable upon the occurrence of certain events, including the issuance by Emisphere of common stock or common stock equivalents at a price which is lower than the current conversion price of the MHR Convertible Notes and lower than the current market price. However, the adjustment provision does not become effective until after the Company raises \$10 million through the issuance of common stock or common stock equivalents at a price which is lower than the current conversion price of the convertible note and lower than the current market price during any consecutive 24 month period. Effective January 1, 2009, the Company adopted the provisions of FASB ASC 815-40-15-5. Under FASB ASC 815-40-15-5, the embedded conversion feature is not considered indexed to the Company's own stock and, therefore, does not meet the scope exception in FASB ASC 815-10-15 and thus needs to be accounted for as a derivative liability. The adoption of FASB ASC 815-40-15-5 requires recognition of the cumulative effect of a change in accounting principles to the opening balance of our accumulated deficit, additional paid in capital, and liability for derivative financial instruments. This liability had been presented as a non-current liability as of December 31, 2010 and has been presented as a current liability as of September 30, 2011 to correspond with its host contract, the MHR Convertible Notes. The fair value of the embedded conversion feature is estimated, at the end of each quarterly reporting period, using Black-Scholes models. The assumptions used in computing the fair value as of September 30, 2011 are a closing stock price of \$1.95, conversion prices of \$3.78 and \$1.95, expected volatility of 100.74% over the remaining term of one year and a risk-free rate of 0.13%. The fair value of the embedded conversion feature decreased by \$1.0 million and \$5.3 million for the three and nine months ended September 30, 2011, respectively, which has been recognized in the accompanying statements of operations. The embedded conversion feature will be adjusted to estimated fair value for each future period they remain outstanding. See Note 9 for a further discussion of the MHR Convertible Notes.

MHR 2006 Warrants. In connection with the exercise of the MHR Option in April 2006 discussed in Note 9 above, the Company issued to MHR warrants to purchase 617,211 shares for proceeds of \$0.6 million. The MHR 2006 Warrants had an original exercise price of \$4.00 and were exercisable through September 26, 2011. The MHR 2006

Warrants had the same terms as the August 2007 Warrants (see below). The anti-dilution feature of the MHR 2006 Warrants was triggered in connection with the August 2007 Financing, resulting in an adjusted exercise price of \$3.76. Based on the provisions of FASB ASC 815, *Derivatives and Hedging*, the MHR 2006 Warrants have been determined to be an embedded derivative instrument which must be separated from the host contract. The MHR 2006 Warrants contained the same potential cash settlement provisions as the August 2007 Financing Warrants and, therefore, they have been accounted for as a separate liability. The fair value of the MHR 2006 Warrants is estimated at the end of each quarterly period that they remain outstanding using Black-Scholes models. The MHR 2006 Warrants expired September 26, 2011. The fair value of the MHR 2006 Warrants decreased by \$1 thousand and \$0.6 million for the three and nine months ended September 30, 2011, respectively, which has been recognized in the accompanying statement of operations.

Table of Contents

August 2007 Warrants. In connection with an equity financing in August 2007 (the August 2007 Financing), Emisphere sold warrants to purchase up to 400,000 shares of common stock (the August 2007 Warrants). Of these 400,000 warrants, 91,073 were sold to MHR. Each of the August 2007 Warrants were issued with an exercise price of \$3.948 and expire on August 21, 2012. The August 2007 Warrants provide for certain anti-dilution protection as provided therein. Under the terms of the August 2007 Warrants, we have an obligation to make a cash payment to the holders of the August 2007 Warrants for any gain that could have been realized if the holders exercise the August 2007 Warrants and we subsequently fail to deliver a certificate representing the shares to be issued upon such exercise by the third trading day after such August 2007 Warrants have been exercised. Accordingly, the August 2007 Warrants have been accounted for as a liability. The fair value of the warrants is estimated, at the end of each quarterly reporting period, using the Black-Scholes model. The assumptions used in computing the fair value as of September 30, 2011 are a closing stock price of \$1.95, expected volatility of 100.54% over the remaining term of eleven months and a risk-free rate of 0.13%. The fair value of the August 2007 Warrants increased \$0.05 million for the three months ended September 30, 2011 and decreased \$0.35 million for the nine months ended September 30, 2011, respectively, which has been recognized in the accompanying statements of operations. The August 2007 Warrants will be adjusted to estimated fair value for each future period they remain outstanding.

August 2009 Warrants. In connection with an equity financing in August 2009 (the August 2009 Financing), Emisphere sold warrants to purchase 6.4 million shares of common stock to MHR (3.7 million) and other unrelated investors (2.7 million) (the August 2009 Warrants). The August 2009 Warrants were issued with an exercise price of \$0.70 and expire on August 21, 2014. Under the terms of the August 2009 Warrants, we have an obligation to make a cash payment to the holders of the August 2009 Warrants for any gain that could have been realized if the holders exercise the August 2009 Warrants and we subsequently fail to deliver a certificate representing the shares to be issued upon such exercise by the third trading day after such August 2009 Warrants have been exercised. Accordingly, the August 2009 Warrants have been accounted for as a liability. The fair value of the August 2009 Warrants is estimated, at the end of each quarterly reporting period, using the Black-Scholes model. The assumptions used in computing the fair value as of September 30, 2011 are a closing stock price of \$1.95, expected volatility of 124.35% over the remaining term of two years and eleven months and a risk-free rate of 0.42%. The fair value of the August 2009 Warrants increased \$3.5 million for the three months ended September 30, 2011 and decreased \$1.7 million for the nine months ended September 30, 2011, respectively, which has been recognized in the accompanying statements of operations. The warrants will be adjusted to estimated fair value for each future period they remain outstanding. During the year ended December 31, 2010, the unrelated investors exercised their warrants to purchase up to 2,685,714 million shares of the Company's common stock at an exercise price of \$0.70, using the cashless exercise provision. The Company issued an aggregate of 1,966,937 shares to such holders in accordance with the terms of the cashless exercise provision. The Company calculated the fair value of the 2,685,714 exercised warrants on their respective exercise dates using the Black-Scholes model. The weighted average assumptions used in computing the fair values were a closing stock price of \$1.91, expected volatility of 101.99% over the remaining contractual life of four years, three months and a risk-free rate of 1.46%. The fair value of the 2,685,714 exercised warrants increased by \$2.2 million from January 1, 2010 through the date of exercise, and this increase has been recognized in the accompanying statements of operations. The fair value of the derivative liabilities at the exercise dates of \$4.3 million was reclassified to additional paid-in-capital. After these cashless exercises, warrants to purchase up to 3,729,323 shares of common stock, in the aggregate, remain outstanding.

June 2010 MHR Warrants. As consideration for its consent and limitation of rights in connection with the Novartis Agreement, the Company granted MHR warrants to purchase 865,000 shares of its common stock under the MHR Letter Agreement. The June 2010 MHR Warrants are exercisable at \$2.90 per share and will expire on August 21, 2014. The June 2010 MHR Warrants provide for certain anti-dilution protection as provided therein. We have an obligation to make a cash payment to the holders of the warrants for any gain that could have been realized if the holders exercise the June 2010 MHR Warrants and we subsequently fail to deliver a certificate representing the shares to be issued upon such exercise by the third trading day after such June 2010 MHR Warrants have been exercised. Accordingly, the June 2010 MHR Warrants have been accounted for as a liability. Their fair value is estimated, at the end of each quarterly reporting period, using the Black-Scholes model. The Company estimated the fair value of the

June 2010 MHR Warrants on the date of grant using Black-Scholes models to be \$1.9 million, which triggered the recognition of extinguishment and restructuring accounting for the MHR Convertible Notes. The assumptions used in computing the fair value of the June 2010 MHR Warrants at September 30, 2011 are closing stock prices of \$1.95, \$0.44, and \$2.89, exercise prices of \$1.95, \$0.44, \$2.89, and \$2.90, expected volatility of 124.35% over the remaining two years and eleven months, and a risk-free rate of 0.42%. The fair value of the June 2010 MHR Warrants increased by \$0.5 million for the three months ended September 30, 2011 and decreased \$0.4 million for the nine months ended September 30, 2011, respectively, which has been recognized in the accompanying statements of operations. The June 2010 MHR Warrants will be adjusted to estimated fair value for each future period they remain outstanding.

August 2010 Warrants. On August 25, 2010, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company agreed to sell an aggregate of 3,497,528 shares of its common stock and warrants to purchase a total of 2,623,146 additional shares of its common stock for total gross proceeds of \$3,532,503 (together with the

Table of Contents

transactions contemplated by the MHR August 2010 Securities Purchase Agreement, as defined below, the

August 2010 Financing). Each unit, consisting of one share of common stock and a warrant to purchase 0.75 shares of common stock, was sold at a purchase price of \$1.01. The warrants to purchase additional shares are exercisable at a price of \$1.26 per share and will expire five years from the date of issuance. In accordance with the terms of a registration rights agreement with the investors, the Company filed a registration statement on September 15, 2010, which was declared effective October 12, 2010. On August 25, 2010, the Company also announced that it had entered into a separate securities purchase agreement with MHR as part of the August 2010 Financing (the MHR August 2010 Securities Purchase Agreement), pursuant to which the Company agreed to sell an aggregate of 3,497,528 shares of its common stock and warrants to purchase a total of 2,623,146 additional shares of its common stock for total gross proceeds of \$3,532,503. Each unit, consisting of one share of common stock and a warrant to purchase 0.75 shares of common stock, was sold at a purchase price of \$1.01. The warrants to purchase additional shares are exercisable at a price of \$1.26 per share and will expire five years from the date of issuance. In connection with the August 2010 Financing, Emisphere sold warrants to purchase 5.2 million shares of common stock to MHR (2.6 million) and other unrelated investors (2.6 million) (the August 2010 Warrants). The August 2010 Warrants were issued with an exercise price of \$1.26 and expire on August 26, 2015. Under the terms of the August 2010 Warrants, we have an obligation to make a cash payment to the holders of the August 2010 Warrants for any gain that could have been realized if the holders exercise the August 2010 Warrants and we subsequently fail to deliver a certificate representing the shares to be issued upon such exercise by the third trading day after such August 2010 Warrants have been exercised.

Accordingly, the August 2010 Warrants have been accounted for as a liability. The fair value of the warrants is estimated, at the end of each quarterly reporting period, using the Black-Scholes model. On January 12, 2011, one of the unrelated investors notified the Company of its intention to exercise 0.2 million warrants. The Company received proceeds of \$0.2 million from the exercise of these warrants. The Company calculated the fair value of the 0.2 million exercised warrants on January 12, 2011 using the Black-Scholes option pricing model. The assumptions used in computing the fair value as of January 12, 2011 are a closing stock price of \$2.25, expected volatility of 107.30% over the remaining contractual life of four years and seven months and a risk-free rate of 1.99%. The fair value of the 0.2 million exercised warrants decreased by approximately \$28,000 for the period from January 1, 2011 through January 12, 2011, which has been recognized in the accompanying statements of operations. The assumptions used in computing the fair value of the remaining August 2010 Warrants as of September 30, 2011 are a closing stock price of \$1.95, exercise price of \$1.26, expected volatility of 117.41% over the remaining term of three years and eleven months, and a risk-free rate of 0.42%. The fair value of the August 2010 Warrants increased by \$4.7 million for the three months ended September 30, 2011 and decreased \$2.2 million for the nine months ended September 30, 2011, respectively, which has been recognized in the accompanying statements of operations. The August 2010 Warrants will be adjusted to estimated fair value for each future period they remain outstanding.

August 2010 MHR Waiver Warrants. In connection with the August 2010 Financing, the Company entered into a waiver agreement with MHR, pursuant to which MHR waived certain anti-dilution adjustment rights under the MHR Convertible Notes and certain warrants issued by the Company to MHR that would otherwise have been triggered by the August 2010 Financing. As consideration for such waiver, the Company issued to MHR warrants to purchase 975,000 shares of its common stock (the August 2010 MHR Waiver Warrants). The August 2010 MHR Waiver Warrants are in the same form of warrant as the August 2010 Warrants issued to MHR as part of the August 2010 Financing described above. Accordingly, the August 2010 MHR Waiver Warrants have been accounted for as a liability. The fair value of the August 2010 MHR Waiver Warrants is estimated, at the end of each quarterly reporting period, using Black-Scholes models. The Company estimated the fair value of the warrants on the date of grant using Black-Scholes models to be \$0.8 million. The assumptions used in computing the fair value of the August 2010 MHR Waiver Warrants at September 30, 2011 are a closing stock price of \$1.95, exercise price of \$1.26, expected volatility of 117.41% over the term of three years and eleven months, and a risk free rate of 0.42%. The fair value of the August 2010 MHR Waiver Warrants increased by \$0.9 million for the three months ended September 30, 2011 and decreased \$0.4 million for the nine months ended September 30, 2011, respectively, and the decrease has been recognized in the accompanying statements of operations. The August 2010 MHR Waiver Warrants will be adjusted to estimated fair value for each future period they remain outstanding.

July 2011 Warrants. On July 6, 2011, as part of the July 2011 Financing, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company agreed to sell an aggregate of 4,300,438 shares of its common stock and warrants to purchase a total of 3,010,306 additional shares of its common stock for total gross proceeds of \$3,749,982. Each unit, consisting of one share of common stock and a warrant to purchase 0.7 shares of common stock, was sold at a purchase price of \$0.872. The warrants to purchase additional shares are exercisable at a price of \$1.09 per share and will expire five years from the date of issuance. In accordance with the terms of a registration rights agreement with the investors, the Company filed a registration statement on July 26, 2011, which was declared effective October 12, 2011. On July 6, 2011, the Company also announced that it had entered into a separate securities purchase agreement with MHR as part of the July 2011 Financing, pursuant to which the Company agreed to sell an aggregate of 4,300,438 shares of its common stock and warrants to purchase a total of 3,010,306 additional shares of its common stock for total gross proceeds of \$3,749,982. Each unit, consisting of one share of common stock and a warrant to purchase 0.7 shares of common stock, was sold at a purchase price of \$0.872. The warrants to purchase additional shares are exercisable at a price of \$1.09 per share and will expire five years from the date of issuance. In connection with the July 2011 Financing, Emisphere sold warrants to purchase 6.02 million shares of common stock to MHR (3.01 million) and other unrelated investors (3.01 million) (the July 2011 Warrants). The July 2011 Warrants were issued with an exercise price of \$1.09 and expire on July 6, 2016. Under the terms of the July 2011 Warrants, we have an obligation to make a cash payment to the holders of the July

Table of Contents

2011 Warrants for any gain that could have been realized if the holders exercise the July 2011 Warrants and we subsequently fail to deliver a certificate representing the shares to be issued upon such exercise by the third trading day after such July 2011 Warrants have been exercised. Accordingly, the July 2011 Warrants have been accounted for as a liability. The fair value of the warrants is estimated, at the end of each quarterly reporting period, using the Black-Scholes model. The Company estimated the fair value of the warrants as of the date of grant using Black-Scholes models to be \$4.5 million. The assumptions used in computing the fair value of the July 2011 Warrants as of September 30, 2011 are a closing stock price of \$1.95, exercise price of \$1.09, expected volatility of 110.35% over the remaining term of four years and ten months, and a risk-free rate of 0.96%. The fair value of the July 2011 Warrants increased by \$5.3 million from the date of issue until the quarter ended September 30, 2011 and the fluctuation has been recorded in the statements of operations.

July 2011 MHR Waiver Warrants. In connection with the July 2011 Financing, the Company entered into a waiver agreement with MHR, pursuant to which MHR waived certain anti-dilution adjustment rights under the MHR Convertible Notes and certain warrants issued by the Company to MHR that would otherwise have been triggered by the July 2011 Financing. As consideration for such waiver, the Company issued to MHR warrants to purchase 795,000 shares of its common stock (the July 2011 MHR Waiver Warrants). The July 2011 MHR Waiver Warrants are in the same form of warrant as the July 2011 Warrants issued to MHR described above. Accordingly, the July 2011 MHR Waiver Warrants have been accounted for as a liability. The fair value of the July 2011 MHR Waiver Warrants is estimated, at the end of each quarterly reporting period, using Black-Scholes models. The Company estimated the fair value of the warrants on the date of grant using Black-Scholes models to be \$0.6 million. The assumptions used in computing the fair value of the July 2011 MHR Waiver Warrants at September 30, 2011 are a closing stock price of \$1.95, exercise price of \$1.09, expected volatility of 110.35% over the term of four years and ten months, and a risk free rate of 0.96%. The fair value of the July 2011 MHR Waiver Warrants increased by \$0.7 million from the date of issue until the quarter ended September 30, 2011 and the fluctuation has been recorded in the statements of operations.

11. Stockholders Deficit

On July 6, 2011, we completed the July 2011 Financing, which included the sale of 4,300,438 shares of common stock and 3,010,306 warrants to purchase shares of common stock to certain institutional investors for gross proceeds of \$3,749,982 and the sale of 4,300,438 shares of common stock and 3,010,306 warrants to purchase shares of common stock to MHR for gross proceeds of \$3,749,982. Proceeds from the offering, net of cash issuance costs of \$0.3 million, were \$7.2 million. Additional issuance costs consisted of \$0.6 million from the issuance of the July 2011 MHR Waiver Warrants, as described in Note 10 above, and \$25,000 in accrued expenses to reimburse MHR for its legal fees, each in consideration of waiving certain anti-dilution adjustments rights under the MHR Convertible Notes and certain warrants issued by the Company to MHR that would otherwise have been triggered by the July 2011 Financing.

12. Net income (loss) per share

The following table sets forth the information needed to compute basic earnings per share:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2011 (in thousands except per share data)	2010 Restated (in thousands except per share data)	2011 (in thousands except per share data)	2010 Restated (in thousands except per share data)
Basic net income (loss)	\$ (17,606)	\$ 10,082	\$ (4,764)	\$ (38,750)
Effect of dilutive securities MHR convertible note assumed conversion				
Numerator for diluted net income (loss) per share after assumed note conversion	(17,606)	10,082	(4,764)	(38,750)

Weighted average common shares outstanding:	60,122,747	47,401,395	54,811,423	44,291,889
Dilutive securities				
Options		410,378		
Warrants		3,111,108		

Diluted weighted average common shares outstanding and assumed conversion	60,122,747	50,922,881	54,811,423	44,291,889
---	------------	------------	------------	------------

Basic net income (loss) per share	\$ (0.29)	\$ 0.21	\$ (0.09)	\$ (0.87)
Diluted net income (loss) per share	\$ (0.29)	\$ 0.20	\$ (0.09)	\$ (0.87)

For the three and nine months periods ended September 30, 2011 and 2010, certain potential shares of common stock have been excluded from the calculation of diluted income (loss) per share because the exercise price was greater than the average market price

Table of Contents

of our common stock, and therefore, the effect on diluted loss per share would have been anti-dilutive. In addition, incremental shares from the assumed conversion of the MHR note payable are excluded for the three and nine month periods ended September 30, 2011 and 2010 as the effect of these shares is anti-dilutive in these periods. The following table sets forth the number of potential shares of common stock that have been excluded from diluted net income (loss) per share because their effect was anti-dilutive.

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2011	2010	2011	2010
Options to purchase common shares	3,200,650	2,815,088	3,200,650	3,225,466
Outstanding warrants	17,843,727	8,721,717	17,843,727	11,832,826
MHR convertible note payable	7,246,873	6,495,250	7,246,873	6,495,250
	28,291,250	18,032,055	28,291,250	21,553,542

13. Commitments and Contingencies

Commitments. At the beginning of 2009 we had leased approximately 80,000 square feet of office space at 765 Old Saw Mill River Road, Tarrytown, NY (the Tarrytown Facility) for use as administrative offices and laboratories. The lease for the Tarrytown Facility (the Lease) had been set to expire on August 31, 2012. However, on April 29, 2009 (the Execution Date), the Company entered into a Lease Termination Agreement (the Lease Termination Agreement) with BMR-Landmark at Eastview, LLC, a Delaware limited liability company (BMR) pursuant to which the Company and BMR terminated the lease of the Tarrytown Facility. Pursuant to the Lease Termination Agreement, the Lease was terminated effective as of April 1, 2009. The Lease Termination Agreement provided that the Company make the following payments to BMR: (a) \$1 million, paid on the Execution Date, (b) \$0.5 million, paid six months after the Execution Date, and (c) \$0.75 million, payable twelve months after the Execution Date. Initial and six months payments were made on schedule. Although the final payment was due originally on April 29, 2010, on March 17, 2010 the Company and BMR agreed to amend the Lease Termination Agreement (the Amendment). According to the Amendment, the final payment was modified as follows: the Company was to pay Eight Hundred Thousand Dollars (\$800,000), as follows: (i) Two Hundred Thousand Dollars (\$200,000) within five (5) days after the execution date of the Amendment, and (ii) One Hundred Thousand Dollars (\$100,000) on each of the following dates: July 15, 2010, August 15, 2010, September 15, 2010, October 15, 2010, November 15, 2010, and December 15, 2010. Through July 1, 2011, the Company paid in full \$800,000 of principal plus \$28,250 interest for late payments in accordance with the terms of the Lease Termination Agreement, as amended by the Amendment.

We continue to lease office space at 240 Cedar Knolls Road, Suite 200, Cedar Knolls, New Jersey under a non-cancellable operating lease expiring in 2013.

The Company evaluates the financial consequences of legal actions periodically or as facts present themselves and books accruals to account for its best estimate of future costs accordingly.

Contingencies. In the ordinary course of business, we enter into agreements with third parties that include indemnification provisions which, in our judgment, are normal and customary for companies in our industry sector. These agreements are typically with business partners, clinical sites, and suppliers. Pursuant to these agreements, we generally agree to indemnify, hold harmless, and reimburse indemnified parties for losses suffered or incurred by the indemnified parties with respect to our product candidates, use of such product candidates, or other actions taken or omitted by us. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. We have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of liabilities relating to these provisions is minimal. Accordingly, we have no liabilities recorded for these provisions as of September 30, 2011.

In the normal course of business, we may be confronted with issues or events that may result in a contingent liability. These generally relate to lawsuits, claims, environmental actions or the action of various regulatory agencies. If necessary, management consults with counsel and other appropriate experts to assess any matters that arise. If, in our opinion, we have incurred a probable loss as set forth by accounting principles generally accepted in the U.S., an

estimate is made of the loss and the appropriate accounting entries are reflected in our financial statements. After consultation with legal counsel, we do not anticipate that liabilities arising out of currently pending or threatened lawsuits and claims will have a material adverse effect on our financial position, results of operations or cash flows.

Table of Contents**14. Restructuring Expense**

On December 8, 2008, as part of our efforts to improve operational efficiency we decided to close our research and development facilities in Tarrytown, NY, which resulted in a restructuring charge of approximately \$3.8 million in the fourth quarter 2008. As described in Note 13 above, on April 29, 2009, the Company entered into the Lease Termination Agreement with BMR, and credited the restructuring charge of \$0.35 million in accordance with the terms of the Lease Termination Agreement. On March 17, 2010 the Company and BMR amended the Lease Termination Agreement as described in Note 13 above. Consequently, the restructuring liability was readjusted to reflect the terms of the Amendment accordingly.

Adjustments to the restructuring liability are as follows (\$ thousands):

	Liability at December 31, 2010	Cash Payments	Adjustment to the Liability	Liability at June 30, 2011
Lease restructuring expense	\$ 300	\$ (300)	\$	\$

15. Income Taxes

The Company is primarily subject to United States federal and New Jersey state income tax. The Company's policy is to recognize interest and penalties related to income tax matters in income tax expense. As of December 31, 2010 and September 30, 2011, the Company had no accruals for interest or penalties related to income tax matters. For the three and nine month periods ended September 30, 2011 and 2010, the effective income tax rate was 0%. The difference between the Company's effective income tax rate and the Federal statutory rate of 35% is attributable to state tax benefits and tax credits offset by changes in the deferred tax valuation allowance.

16. New Accounting Pronouncements

In September 2011, the FASB issued Accounting Standards Update No. 2011-08 (ASU 2011-08), which updates the guidance in ASC Topic 350, *Intangibles—Goodwill & Other*. The amendments in ASU 2011-08 permit an entity to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test described in ASC Topic 350. The more-likely-than-not threshold is defined as having a likelihood of more than fifty percent. If, after assessing the totality of events or circumstances, an entity determines that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is unnecessary. The amendments in ASU 2011-08 include examples of events and circumstances that an entity should consider in evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. However, the examples are not intended to be all-inclusive and an entity may identify other relevant events and circumstances to consider in making the determination. The examples in this ASU 2011-08 supersede the previous examples under ASC Topic 350 of events and circumstances an entity should consider in determining whether it should test for impairment between annual tests, and also supersede the examples of events and circumstances that an entity having a reporting unit with a zero or negative should consider in determining whether to perform the second step of the impairment test. Under the amendments in ASU 2011-08, an entity is no longer permitted to carry forward its detailed calculation of a reporting unit's fair value from a prior year as previously permitted under ASC Topic 350. ASU 2011-08 is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011. ASU 2011-08 is not expected to have a material impact on the Company's financial position or results of operations.

In May 2011, the FASB issued Accounting Standards Update 2011-04 (ASU 2011-04), which updated the guidance in ASC Topic 820, *Fair Value Measurement*. The amendments in ASU 2011-04 generally represent clarifications of Topic 820, but also include some instances where a particular principle or requirement for measuring fair value or disclosing information about fair value measurements has changed. ASU 2011-04 results in common principles and requirements for measuring fair value and for disclosing information about fair value measurements in accordance with U.S. GAAP and International Financial Reporting Standards. The amendments in ASU 2011-04 are to be applied prospectively. For public entities, the amendments are effective for interim and annual periods beginning after

December 15, 2011, and early application is not permitted. ASU 2011-04 is not expected to have a material impact on the Company's financial position or results of operations.

In December 2010, the FASB issued ASU 2010-29, *Business Combinations (ASC Topic 805): Disclosure of Supplementary Pro Forma Information for Business Combinations* (ASU 2010-29). The amendments in ASU 2010-29 affect any public entity as defined by ASC Topic 805 that enters into business combinations that are material on an individual or aggregate basis. The amendments in ASU 2010-29 specify that if a public entity presents comparative financial statements, the entity should disclose

Table of Contents

revenue and earnings of the combined entity as though the business combination(s) that occurred during the current year had occurred as of the beginning of the comparable prior annual reporting period only. The amendments also expand the supplemental pro forma disclosures to include a description of the nature and amount of material, nonrecurring pro forma adjustments directly attributable to the business combination included in the reported pro forma revenue and earnings. The amendments in ASU 2010-29 are effective prospectively for business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2010. The adoption of ASU 2010-29 did not have a material impact on the Company's results of operations or financial condition.

In December 2010, the FASB issued ASU 2010-28, *Intangibles—Goodwill and Other (ASC Topic 350): When to Perform Step 2 of the Goodwill Impairment Test for Reporting Units with Zero or Negative Carrying Amounts* (ASU 2010-28). The amendments in ASU 2010-28 modify Step 1 of the goodwill impairment test for reporting units with zero or negative carrying amounts. For those reporting units, an entity is required to perform Step 2 of the goodwill impairment test if it is more likely than not that a goodwill impairment exists. In determining whether it is more likely than not that goodwill impairment exists, an entity should consider whether there are any adverse qualitative factors indicating that an impairment may exist. The qualitative factors are consistent with the existing guidance and examples, which require that goodwill of a reporting unit be tested for impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. For public entities, the amendments in ASU 2010-28 are effective for fiscal years, and interim periods within those years, beginning after December 15, 2010. The adoption of ASU 2010-28 did not have a material impact on the Company's results of operations or financial condition.

In April 2010, the FASB issued ASU 2010-17, *Revenue Recognition—Milestone Method* (ASU 2010-17). ASU 2010-17 provides guidance on the criteria that should be met for determining whether the milestone method of revenue recognition is appropriate. A vendor can recognize consideration that is contingent upon achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone meets all criteria to be considered substantive. The following criteria must be met for a milestone to be considered substantive: the consideration earned by achieving the milestone should (i) be commensurate with either the level of effort required to achieve the milestone or the enhancement of the value of the item delivered as a result of a specific outcome resulting from the vendor's performance to achieve the milestone; (ii) be related solely to past performance; and (iii) be reasonable relative to all deliverables and payment terms in the arrangement. No bifurcation of an individual milestone is allowed and there can be more than one milestone in an arrangement. Accordingly, an arrangement may contain both substantive and non-substantive milestones. ASU 2010-17 is effective on a prospective basis for milestones achieved in fiscal years, and interim periods within those years, beginning on or after June 15, 2010. The adoption of ASU 2010-17 did not have a material effect on the Company's results of operations or financial condition.

In October 2009, the FASB issued ASU 2009-13, *Multiple-Deliverable Revenue Arrangements* (ASU 2009-13). ASU 2009-13 requires entities to allocate revenue in an arrangement using estimated selling prices of the delivered goods and services based on a selling price hierarchy. The amendments in ASU 2009-13 eliminate the residual method of revenue allocation and require revenue to be allocated using the relative selling price method. ASU 2009-13 should be applied on a prospective basis for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010, with early adoption permitted. The adoption of ASU 2009-13 did not have a material impact on the Company's results of operations or financial condition.

Management does not believe there would have been a material effect on the accompanying financial statements had any other recently issued, but not yet effective, accounting standards been adopted in the current period.

17. Fair Value

In accordance with FASB ASC 820, *Fair Value Measurements and Disclosures*, the following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2011 and December 31, 2010:

Level 2**Level 2**

	September 30, 2011 (\$ thousands)	December 31, 2010 (\$ thousands)
Derivative instruments (short term)	\$ 33,820	\$ 22,940
Derivative instruments (long term)		11,166
Total	\$ 33,820	\$ 34,106

Table of Contents

Some of the Company's financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate fair value due to their liquid or short-term nature, such as cash and cash equivalents, receivables and payables.

We have determined that it is not practical to estimate the fair value of our notes payable because of their unique nature and the costs that would be incurred to obtain an independent valuation. We do not have comparable outstanding debt on which to base an estimated current borrowing rate or other discount rate for purposes of estimating the fair value of the notes payable and we have not been able to develop a valuation model that can be applied consistently in a cost efficient manner. These factors all contribute to the impracticability of estimating the fair value of the notes payable. At September 30, 2011, the carrying value of the notes payable and accrued interest was \$27.4 million.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

SAFE HARBOR CAUTIONARY STATEMENT

Certain statements in this Management's Discussion and Analysis of Financial Conditions and Results of Operations and elsewhere in this report as well as statements made from time to time by our representatives may constitute

forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include (without limitation) statements regarding planned or expected studies and trials of oral formulations that utilize our Eligen® Technology; the timing of the development and commercialization of our product candidates or potential products that may be developed using our Eligen® Technology; the potential market size, advantages or therapeutic uses of our potential products; variation in actual savings and operational improvements resulting from restructurings; and the sufficiency of our available capital resources to meet our funding needs. We do not undertake any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results or achievements expressed or implied by such forward-looking statements. Such factors include the factors described under Part II, Item 1A. Risk Factors and other factors discussed in connection with any forward-looking statements.

General

Emisphere Technologies, Inc. is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules or nutritional supplements using its Eligen® Technology. These molecules could be available currently or are under development. Such molecules are usually delivered by injection; in many cases, their benefits are limited due to poor bioavailability, slow onset of action or variable absorption. In those cases, our technology may increase the benefit of the therapy by improving the absorption of a therapeutic molecule thereby increasing its bioavailability, or by decreasing the time to peak blood concentrations which could result in faster onset of the molecule's therapeutic action. The Eligen® Technology can make it possible to deliver certain therapeutic molecules orally, without altering their chemical form or biological activity. Eligen® delivery agents, or carriers, facilitate or enable the transport of therapeutic molecules across the mucous membranes of the gastrointestinal tract, to reach the general circulation where they dissociate from the carrier and are free to elicit their pharmacological effect. The Eligen® Technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal.

Since our inception in 1986, substantial efforts and resources have been devoted to understanding the Eligen® Technology and establishing a product development pipeline that incorporated this technology with selected molecules. Our corporate strategy is focused on commercializing the Eligen® Technology as quickly as possible, building high-value partnerships and developing our product pipeline. We develop potential product candidates in-house, as is evident in the development of our higher dose Eligen® B12 (1000 mcg) product, and we enhance the value of the Eligen® Technology through our development partners, including Novartis, Novo Nordisk A/S (Novo Nordisk) and others. Further development, exploration and commercialization of the technology entail risk and operational expenses. However, we continue to focus our efforts on strategic development initiatives as well as cost control, and aggressively seek to reduce non-strategic spending.

The application of the Eligen® Technology is potentially broad and may provide for a number of opportunities across a spectrum of therapeutic modalities or nutritional supplements. During the third quarter 2011, we continued to develop our product pipeline utilizing the Eligen® Technology with prescription and non-prescription product candidates. We prioritized our development efforts based on overall potential returns on investment, likelihood of success, and market and medical need. Our goal is to implement our

Table of Contents

Eligen® Technology to enhance overall healthcare, including patient accessibility and compliance, while benefiting the commercial pharmaceutical marketplace and driving company valuation. Investments required to continue developing our product pipeline may be partially paid by income-generating license arrangements whose value tends to increase as product candidates move from pre-clinical into clinical development. It is our intention that investments that may be required to fund our research and development will be approached incrementally in order to minimize disruption or dilution.

We are planning to expand our current collaborative relationships to take advantage of the critical knowledge that others have gained by working with our technology. We will also continue to pursue product candidates for internal development and commercialization. We believe that these internal candidates must be capable of development with reasonable investments in an acceptable time period and with a reasonable risk-benefit profile.

Our product pipeline includes prescription, medical food and nutritional supplements product candidates that are being developed in partnership or internally. During 2010 our development partners Novartis and Novo Nordisk continued or expanded their development programs and we continued to make progress on our internally developed Eligen® B12 product.

Novartis is using our Eligen® drug delivery technology in combination with salmon calcitonin. Their most advanced program utilizing the Company's Eligen® Technology is testing an oral formulation of calcitonin to treat osteoarthritis and osteoporosis. For osteoarthritis, Novartis completed two Phase III trials. Novartis is also conducting a Phase III clinical study for osteoporosis. Novartis recently informed Emisphere that its Phase III study of oral calcitonin in osteoporosis has been completed and first interpretable results are expected in the fourth quarter of 2011.

Novartis and its license partner Nordic Bioscience A/S (Nordic Bioscience) recently completed the Phase III Study 2302, assessing the safety and efficacy of oral calcitonin (oCT) in the treatment of osteoarthritis of the knee. Study 2302, along with its companion Study 2301, incorporates Emisphere's unique and proprietary Eligen® Drug Delivery Technology for the improved oral absorption of salmon calcitonin. Novartis has recently informed Emisphere that it has reviewed the first interpretable results of Study 2302 and has advised the Company of its top line conclusions as follows: Preliminary analysis of two year study data showed both co-primary endpoints and secondary endpoints of the study were not met. Additionally, preliminary analysis of Study 2302 data showed a positive safety profile.

In addition, Nordic Bioscience recently published the results from the two-year Study 2301, the companion study to Study 2302, in the Osteoarthritis Research Society International (OARSI) Abstract #64, Volume 19, Supplement 1 (ISSN 1063-4584). The OARSI abstract contains the conclusion twice daily oCT over 2 years resulted in a significant symptom-modifying efficacy in patients with painful knee OA as assessed by WOMAC pain, physical function, and stiffness scores. Although improvement on the primary endpoint of JSW (joint-space width) was not reached, there was an increase in cartilage volume vs. placebo indicating some structure-modifying efficacy.

Novartis has not provided Emisphere with any further data from either Study 2302 or Study 2301 at this time. Nordic Bioscience and Novartis have indicated that they are going to continue to collaborate to further analyze and evaluate the results.

On August 3, 2011, the Company received notification from Novartis that Novartis will be terminating that certain Research Collaboration and License Agreement by and among the Company and Novartis (the Oral HGH Agreement), dated September 22, 2004, as amended (the Termination). The Oral HGH Agreement provided for collaboration between the Company and Novartis on clinical trials of an oral human growth hormone product using the Eligen® Technology and provided Novartis with an exclusive worldwide license to develop, make, have made, use and sell products developed under the program. In connection with the Termination, Emisphere may continue to develop and/or commercialize the product.

The Termination was effective as of October 26, 2011. In connection with the Oral HGH Agreement and the Termination, Novartis will provide the Company, upon request, with the data generated from the collaboration that would be necessary for the Company to continue to develop and commercialize an oral human growth hormone product using the Eligen® Technology. The Company has not incurred any penalties in connection with the Termination.

On June 17, 2011, Novartis informed us of the results of its recently completed Proof of Concept study for an oral PTH1-34 using Emisphere's Eligen® Technology in post-menopausal women with osteoporosis or osteopenia.

Novartis informed us that, although the study confirmed that oral PTH1-34 was both safe and well-tolerated, several clinical endpoints were not met. Based on the data analyzed, Novartis has terminated the study and anticipates no further work on oral formulation of PTH1-34.

Table of Contents

Novo Nordisk is using our Eligen® drug delivery technology in combination with its proprietary GLP-1 receptor agonists and insulins. During December 2010, the Company entered into an exclusive Development and License Agreement with Novo Nordisk to develop and commercialize oral formulations of Novo Nordisk's insulins using Emisphere's Eligen® Technology (the "Insulin Agreement"). This was the second license agreement between the two companies. The first agreement, for the development of oral formulations of GLP-1 receptor agonists, was signed in June 2008, with a potential drug currently in a Phase I clinical trial. The Insulin Agreement included \$57.5 million in potential product development and sales milestone payments to Emisphere, of which \$5 million was paid upon signing, as well as royalties on sales. This extended partnership with Novo Nordisk has the potential to offer significant new solutions to millions of people with diabetes worldwide and it also serves to further validate our Eligen® Technology.

The Company is developing an oral formulation of Eligen® B12 (1000 mcg) for use by B12 deficient individuals. During the fourth quarter 2010, the Company completed a clinical trial which demonstrated that both oral Eligen® B12 (1000 mcg) and injectable B12 (current standard of care) can efficiently and quickly restore normal Vitamin B12 levels in deficient individuals. The manuscript summarizing the results from that clinical trial has been published in the July 2011 edition of the journal *Clinical Therapeutics* (Volume 22, pages 934-945). We also conducted market research to help assess the potential commercial opportunity for our potential Eligen® B12 (1000 mcg) product. On August 5, 2011, we received notice from the United States Patent Office that the U.S. patent application directed to the oral Eligen® B12 formulation was allowed. This new patent provides intellectual property protection for Eligen® B12 through approximately October 2029. Currently, we are evaluating the results of our clinical trials and market research and exploring alternative development and commercialization options with the purpose of maximizing the commercial and health benefits potential of our Eligen® B12 asset.

Our other product candidates in development are in earlier or preclinical research phases, and we continue to assess them for their compatibility with our technology and market needs. Our intent is to seek partnerships with pharmaceutical and biotechnology companies for certain of these products. We plan to expand our pipeline with product candidates that demonstrate significant opportunities for growth.

Results of Operations

Three Months Ended September 30, 2011 Compared to Three Months Ended September 30, 2010:

	2011	Three Months Ended September 30, 2010 (in thousands)	Change
Revenue	\$	\$ 4	\$ (4)
Operating expenses	\$ 1,531	\$ 3,879	\$ (2,348)
Operating loss	\$ (1,531)	\$ (3,875)	\$ (2,344)
Other income (expense)	\$ (16,075)	\$ 13,957	\$ (30,032)
Net income (loss)	\$ (17,606)	\$ 10,082	\$ (27,688)

Revenue decreased \$4 thousand for the three months ended September 30, 2011 compared to the same period last year due to termination of commercial sales of low dose Eligen® B12.

Operating expenses decreased \$2.3 million or 61% for the three months ended September 30, 2011 in comparison to the same period last year. Details of these changes are highlighted in the table below:

	(in thousands)
Decrease in human resources costs	\$ (458)
Decrease in professional fees	(1,022)
Decrease in occupancy costs	
Decrease in clinical costs	(236)

Decrease in depreciation and amortization	(4)
Decrease in other costs	(628)
	\$ (2,348)

Human resource costs decreased \$458 thousand, or 43%, due primarily to a \$399 thousand reduction in wages and wage related costs in 2011 and a \$59 thousand reduction in non-cash compensation commensurate with a reduction in personnel.

Table of Contents

Professional fees decreased \$1.02 million, or 63%, due primarily to a \$554 thousand reduction in legal fees in connection with commercial development efforts and the cancellation of the Novartis Note during 2010, a \$280 thousand decrease in corporate legal fees, and a \$192 thousand decrease in other professional fees.

Clinical costs decreased \$236 thousand, or 94%, due primarily to the completion of our B-12 clinical trial in 2010 and outside lab fees related to formulation and analytical testing incurred during 2010.

Other costs decreased \$628 thousand, or 80%, due primarily to \$542 thousand contract termination expense for discontinuance of the low dose B-12 program and a \$58 thousand charge to settle outstanding lawsuits incurred during 2010 and a \$27 thousand reduction in telecommunication and maintenance costs in 2011.

Our principal operating costs include the following items as a percentage of total operating expenses:

	Three Months Ended September 30,	
	2011	2010
Human resource costs, including benefits	39%	27%
Professional fees for legal, intellectual property, accounting and consulting	39%	42%
Occupancy for our laboratory and operating space	6%	2%
Clinical costs	1%	7%
Depreciation and amortization	5%	2%
Other	10%	20%

Other expenses for the three months ended September 30, 2011 increased \$30.0 million, due primarily to a \$14.6 million expense from the change in fair value of derivative instruments in 2011 arising from the increase in the price of the Company's stock during the third quarter 2011, compared to a \$14.6 million gain from the change in fair value of derivatives arising from the decrease in the price of the Company's stock during the third quarter 2010; proceeds of \$0.5 million from the sale of patents in 2010; and a \$0.3 million increase in interest expense net of other income.

As a result of the above factors, we had a net loss of \$17.6 million for the three months ended September 30, 2011, compared to a net income of \$10.1 million for the three months ended September 30, 2010.

Nine Months Ended September 30, 2011 Compared to Nine Months Ended September 30, 2010:

	Nine Months Ended September 30,		
	2011	2010	Change
		(in thousands)	
Revenue	\$	\$ 55	\$ 55
Operating expenses	\$ 5,806	\$ 10,055	\$ (4,249)
Operating loss	\$ (5,806)	\$ (10,000)	\$ (4,194)
Other income (expense)	\$ 1,042	\$ (28,750)	\$ 29,792
Net income (loss)	\$ (4,764)	\$ (38,750)	\$ 33,986

Revenue decreased \$55 thousand for the nine months ended September 30, 2011 compared to the same period last year due to termination of commercial sales of low dose Eligen® B12.

Operating expenses decreased \$4.2 million or 42% for the nine months ended September 30, 2011 in comparison to the same period last year. Details of these changes are highlighted in the table below:

	(in thousands)
Decrease in human resources costs	\$ (1,600)
Decrease in professional fees	(1,258)
Increase in occupancy costs	4
Decrease in clinical costs	(410)

Decrease in depreciation and amortization	(14)
Decrease in other costs	(971)
	\$ (4,249)

Table of Contents

Human resource costs decreased \$1,600 thousand, or 42%, due primarily to a \$1,135 thousand reduction in wages and wage related costs, and a \$465 thousand reduction in non-cash compensation commensurate with a reduction in personnel.

Professional fees decreased \$1,258 thousand, or 34%, due primarily to a \$751 thousand decrease in legal fees in connection with commercial development efforts and the cancellation of the Novartis Note during 2010 and a \$479 thousand decrease in corporate legal fees.

Occupancy costs increased \$4 thousand, or 1%, due to higher common area maintenance costs in the first quarter 2011.

Clinical costs decreased \$410 thousand, or 66%, due primarily to a \$183 thousand decrease in clinical trial costs related to the B 12 trial completed in 2010 and a \$227 thousand decrease in outside lab fees.

Depreciation and amortization costs decreased \$14 thousand, or 6%, due to certain assets being fully depreciated during 2010.

Other costs decreased \$971 thousand, or 68%, due primarily to a \$542 thousand charge for contract termination with Life Extension Foundation in 2010 for cancellation of the low dose B-12 sales agreement; \$278 thousand charge to settle outstanding lawsuits in 2010; additional restructuring costs of \$50 thousand in 2010 for an amendment to a lease termination agreement with BMR-Landmark at Eastview, LLC, a Delaware limited liability company, regarding former administrative and laboratory space leased by the Company; and a \$101 thousand reduction in 2011 in telecommunication, travel, insurance, and other office expenses.

Our principal operating costs include the following items as a percentage of total operating expenses:

	Nine Months Ended September 30,	
	2011	2010
Human resource costs, including benefits	38%	38%
Professional fees for legal, intellectual property, accounting and consulting	42%	37%
Occupancy for our laboratory and operating space	4%	3%
Clinical costs	4%	6%
Depreciation and amortization	4%	2%
Other	8%	14%

Other income increased \$29.8 million, due primarily to the \$17.0 million one-time charges for loss on extinguishment of debt in 2010; a \$13.1 million gain from the change in fair value of derivative instruments in 2011 arising from the decrease in the price of the Company's stock during 2011; financing fees of \$1.9 million in connection with the settlement of the Novartis Note in June 2010; offset by a \$2.2 million increase in interest expense net of other income in 2011.

As a result of the above factors, we had a net loss of \$4.8 million for the nine months ended September 30, 2011, compared to a net loss of \$38.7 million for the nine months ended September 30, 2010.

Liquidity and Capital Resources

Since our inception in 1986, we have generated significant losses from operations and we anticipate that we will continue to generate significant losses from operations for the foreseeable future. As of September 30, 2011, our accumulated deficit was approximately \$485.7 million and our stockholders deficit was approximately \$84.4 million. Our operating loss was \$1.5 million for the three months ended September 30, 2011 compared to an operating loss of \$3.9 million for the three months ended September 30, 2010. Our operating loss for the nine months ended September 30, 2011 was \$5.8 million compared to \$10.0 million for the nine months ended September 30, 2010.

We have limited capital resources and operations to date have been funded primarily with the proceeds from collaborative research agreements, public and private equity and debt financings and income earned on investments. On July 6, 2011, we closed the transactions contemplated by the July 2011 Financing, as further described in the Notes to our Condensed Financial Statements set forth in Part I, Item 1 of this Report, resulting in proceeds, net of cash issuance costs of \$0.03 million, of \$7.2 million. As of September 30, 2011, total cash and cash equivalents was \$4.7 million compared to \$5.3 million as of December 31, 2010. The change in cash relates to the operating loss offset

by changes in accounts payable and non-cash items net of the proceeds from the July 2011 Financing. We anticipate that our existing capital resources, without implementing cost reductions, raising additional capital, or obtaining substantial cash inflows from potential partners for our products, will enable us to continue operations through approximately May 2012. However, this expectation is based on the current operating plan that could change as a result of many

Table of Contents

factors and additional funding may be required sooner than anticipated. These conditions raise substantial doubt about our ability to continue as a going concern. The audit report prepared by our independent registered public accounting firm relating to our financial statements for the year ended December 31, 2010 includes an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern.

While our plan is to raise capital when needed and/or to pursue partnering opportunities, we cannot be sure how much we will need to spend in order to develop, market and manufacture new products and technologies in the future. We expect to continue to spend substantial amounts on research and development, including amounts spent on conducting clinical trials for our product candidates. Further, we will not have sufficient resources to develop fully any new products or technologies unless we are able to raise substantial additional financing on acceptable terms or secure funds from new or existing partners. We cannot assure that financing will be available on favorable terms or at all. Additionally, these conditions may increase the cost to raise capital. If additional capital is raised through the sale of equity or convertible debt securities, the issuance of such securities would result in dilution to our existing stockholders. Additionally, these conditions may increase costs to raise capital and/or result in further dilution. Our failure to raise capital when needed would adversely affect our business, financial condition and results of operations, and could force us to reduce or cease our operations.

If we are successful in raising additional capital to continue operations, our business will still require substantial additional investment that we have not yet secured. For further discussion, see Part II, Item 1A **Risk Factors**.

Off-Balance Sheet Arrangements

As of September 30, 2011, we had no off-balance sheet arrangements. There were no changes in significant contractual obligations during the three months ended September 30, 2011.

Critical Accounting Estimates

Please refer to the Company's Annual Report on Form 10-K filed with the SEC on March 31, 2011 for detailed explanations of its critical accounting estimates, which have not changed significantly during the period ended September 30, 2011.

New Accounting Pronouncements

For a discussion of new accounting pronouncements, see Note 16 set forth in the Notes to Condensed Financial Statements contained in Part I, Item 1 of this Report.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Fair Value of Warrants and Derivative Liabilities. As further described in Note 10 to our Condensed Financial Statements set forth in Part I, Item 1 of this Report, at September 30, 2011, the estimated fair value of derivative instruments was \$33.8 million. We estimate the fair values of these instruments using the Black-Scholes option pricing model which takes into account a variety of factors, including historical stock price volatility, risk-free interest rates, remaining maturity and the closing price of our common stock. Furthermore, the Company computes the fair value of these instruments using multiple Black-Scholes model calculations to account for the various circumstances that could arise in connection with the contractual terms of said instruments. The Company weights each Black-Scholes model calculation based on its estimation of the likelihood of the occurrence of each circumstance and adjusts relevant Black-Scholes model input to calculate the value of the derivative at the reporting date. We are required to revalue this liability each quarter. We believe that the assumption that has the greatest impact on the determination of fair value is the closing price of our common stock. The following table illustrates the potential effect of changes in the assumptions used to calculate fair value:

	Derivatives (in thousands)
25% increase in stock price	\$ 8,969
50% increase in stock price	18,222
5% increase in assumed volatility	850
25% decrease in stock price	(8599)
50% decrease in stock price	(16,697)

5% decrease in assumed volatility

(880)

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

23

Table of Contents

The Company's senior management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer's management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

The Company has evaluated the effectiveness of the design and operation of its disclosure controls and procedures under the supervision of and with the participation of management, including its Interim Chief Executive Officer and Chief Financial Officer, as of the end of the period covered by this report. Based on that evaluation, our Interim Chief Executive Officer and Chief Financial Officer has concluded that our disclosure controls and procedures are effective.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting during the three month period ended September 30, 2011 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II

ITEM 1A. RISK FACTORS

The following risk factors should be read carefully in connection with evaluating our business and the forward-looking statements that we make in this Report and elsewhere (including oral statements) from time to time. Any of the following risks could materially and adversely affect our business, our operating results, our financial condition and the actual outcome of matters as to which forward-looking statements are made in this Report. Our business is subject to many risks, which are detailed further in our Annual Report on Form 10-K as filed with the SEC on March 31, 2011, including:

Financial Risks

We have a history of operating losses and we may never achieve profitability. If we continue to incur losses or we fail to raise additional capital or receive substantial cash inflows from our partners by April 2012, we may be forced to cease operations.

The audit opinion issued by our independent registered public accounting firm relating to our financial statements for the year ended December 31, 2010 contained a going concern explanatory paragraph.

We may not be able to meet the covenants detailed in the Convertible Notes with MHR Institutional Partners IIA LP, which could result in an increase in the interest rate on the Convertible Notes and/or accelerated maturity of the Convertible Notes, which we would not be able to satisfy.

Our stock was de-listed from NASDAQ.

Risks Related to our Business

Our business will suffer if we fail or are delayed in developing and commercializing an improved oral form of Vitamin B12.

We are highly dependent on the clinical success of our product candidates.

We are highly dependent upon collaborative partners to develop and commercialize compounds using our delivery agents.

Our collaborative partners control the clinical development of certain of our drug candidates and may terminate their efforts at will.

Our product candidates are in various stages of development, and we cannot be certain that any will be suitable for commercial purposes.

Table of Contents

Our collaborative partners are free to develop competing products.

Our business will suffer if we cannot adequately protect our patent and proprietary rights.

We may be at risk of having to obtain a license from third parties making proprietary improvements to our technology.

We are dependent on third parties to manufacture and, in some cases, test our products.

We are dependent on our key personnel and if we cannot recruit and retain leaders in our research, development, manufacturing, and commercial organizations, our business will be harmed.

Risks Related to our Industry

Our future business success depends heavily upon regulatory approvals, which can be difficult to obtain for a variety of reasons, including cost. More specifically, the regulatory approval process for nonprescription product candidates will likely vary by the nature of the therapeutic molecule being delivered. In particular, the European Medical Agency (EMA) announced in January 2011 that its committee for Medicinal Products for Human Use has begun to review available data relevant to the potential for increased risk of prostate cancer progression and other types of malignancies in patients taking calcitonin-containing medicines for the prevention of acute bone loss. The announcement indicated that the decision to review followed review of two clinical trials which suggested an increased frequency of malignancies. The EMA indicated it intended to assess the data obtained in the balance of risks and benefits of calcitonin-containing medicines.

Our collaboration partner Novartis manages the clinical development of oral salmon calcitonin, and has indicated to us that it has responded to the EMA 's request for information. Novartis has informed us that it has informed the FDA of the EMA request, and has provided the FDA with relevant data regarding calcitonin at its request.

Significant delays in approval of our oral salmon calcitonin formulation or denial of approval would materially and adversely affect our business and prospects.

We may face product liability claims related to participation in clinical trials for future products.

We face rapid technological change and intense competition.

Other Risks

Provisions of our corporate charter documents, Delaware law, our financing documents and our stockholder rights plan may dissuade potential acquirers or prevent the replacement or removal of our current management and members of our Board of Directors and may thereby affect the price of our common stock.

Our stock price has been and may continue to be volatile.

Future sales of common stock or warrants, or the prospect of future sales, may depress our stock price. For a more complete listing and description of these and other risks that the Company faces, please see our Annual Report for 2010 on Form 10-K as filed with the SEC on March 31, 2011. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.

ITEM 6. EXHIBITS

Exhibit

Number Description of Exhibit

3.1

Amended and Restated Certificate of Incorporation of Emisphere Technologies, Inc., as amended by the Certificate of Amendment of Amended and Restated Certificate of Incorporation of Emisphere Technologies, Inc., dated April 20, 2007 (filed as Exhibit 3.1 to the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2007 and incorporated herein by reference (SEC File No. 000-17758)).

Table of Contents

Exhibit

Number Description of Exhibit

3.2 By-Laws of Emisphere Technologies, Inc., as amended December 7, 1998 (filed as Exhibit 3(ii) to the Quarterly Report on Form 10-Q for the quarterly period ended January 31, 1999) and as further amended on September 23, 2005 (filed as Exhibit 3.1 to the Current Report on Form 8-K filed on September 30, 2005 and incorporated herein by reference (SEC File No. 000-17758)).

3.3 Amendment, effective as of September 11, 2007, to the Amended By-Laws of Emisphere Technologies, Inc. (filed as Exhibit 3.1 to the Current Report on Form 8-K filed on September 14, 2007 and incorporated herein by reference (SEC File No. 000-17758)).

4.1 Restated Rights Agreement dated as of April 7, 2006 between Emisphere Technologies, Inc. and Mellon Investor Services, LLC (filed as Exhibit 1.1 to the Current Report on Form 8-K filed on April 10, 2006 and incorporated herein by reference (SEC File No. 000-17758)).

31.1 Certification of the Interim Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to section 302 of the Sarbanes- Oxley Act of 2002 (filed herewith).

32.1 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes- Oxley Act of 2002 (furnished herewith).

101. XBRL Instance Document.
INS*

101. XBRL Taxonomy Extension Schema Document.
SCH*

101. XBRL Taxonomy Extension Calculation Linkbase Document.
CAL*

101. XBRL Taxonomy Extension Label Linkbase Document.
LAB*

101. XBRL Taxonomy Extension Presentation Linkbase Document.
PRE*

101. XBRL Taxonomy Extension Definition Linkbase Document.
DEF*

* Users of this data are advised that, pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934, and are otherwise not subject to liability under these sections.

Table of Contents

SIGNATURES

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Emisphere Technologies, Inc.

Date: November 8, 2011

/s/ Michael R. Garone

Michael R. Garone

Interim Chief Executive Officer and Chief
Financial Officer (Principal Executive
Officer and Principal Financial and
Accounting Officer)

27

Table of Contents

EXHIBIT INDEX

Exhibit

Number Description of Exhibit

- 3.1 Amended and Restated Certificate of Incorporation of Emisphere Technologies, Inc., as amended by the Certificate of Amendment of Amended and Restated Certificate of Incorporation of Emisphere Technologies, Inc., dated April 20, 2007 (filed as Exhibit 3.1 to the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2007 and incorporated herein by reference (SEC File No. 000-17758)).
- 3.2 By-Laws of Emisphere Technologies, Inc., as amended December 7, 1998 (filed as Exhibit 3(ii) to the Quarterly Report on Form 10-Q for the quarterly period ended January 31, 1999) and as further amended on September 23, 2005 (filed as Exhibit 3.1 to the Current Report on Form 8-K filed on September 30, 2005 and incorporated herein by reference (SEC File No. 000-17758)).
- 3.3 Amendment, effective as of September 11, 2007, to the Amended By-Laws of Emisphere Technologies, Inc. (filed as Exhibit 3.1 to the Current Report on Form 8-K, filed on September 14, 2007 and incorporated herein by reference (SEC File No. 000-17758)).
- 4.1 Restated Rights Agreement dated as of April 7, 2006 between Emisphere Technologies, Inc. and Mellon Investor Services, LLC (filed as Exhibit 1.1 to the Current Report on Form 8-K filed April 10, 2006 and incorporated herein by reference (SEC File No. 000-17758)).
- 31.1 Certification of the Interim Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to section 302 of the Sarbanes- Oxley Act of 2002 (filed herewith).
- 32.1 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes- Oxley Act of 2002 (furnished herewith).
- 101. XBRL Instance Document.
INS*
- 101. XBRL Taxonomy Extension Schema Document.
SCH*
- 101. XBRL Taxonomy Extension Calculation Linkbase Document.
CAL*
- 101. XBRL Taxonomy Extension Label Linkbase Document.
LAB*
- 101. XBRL Taxonomy Extension Presentation Linkbase Document.
PRE*
- 101. XBRL Taxonomy Extension Definition Linkbase Document.
DEF*

*

Users of this data are advised that, pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934, and are otherwise not subject to liability under these sections.

Table of Contents

EXHIBIT 31.1

**CERTIFICATION PURSUANT TO
RULE 13a-14(a) AND 15d-14(a),
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Michael R. Garone, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Emisphere Technologies, Inc;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within that entity, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 8, 2011

/s/ Michael R. Garone
Michael R. Garone
Interim Chief Executive Officer and
Chief Financial Officer

Table of Contents

EXHIBIT 32.1

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Emisphere Technologies, Inc. (the Company) on Form 10-Q for the quarter ending September 30, 2011 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Michael R. Garone, as Interim Chief Executive Officer and Chief Financial Officer of the Company certify, pursuant to and for the purpose of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 8, 2011

/s/ Michael R. Garone
Michael R. Garone
Interim Chief Executive and
Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to Emisphere Technologies, Inc. and will be retained by Emisphere Technologies, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.